Healthcare IT News January 14, 2021
The agency plans to take a “multi-pronged approach” to advancing oversight of machine learning-enabled devices – with an eye toward ensuring patient safety, algorithm transparency and real-world results.
The U.S. Food and Drug Administration this week published its first action plan for how it intends to spur development and oversight of safe, patient-centric artificial intelligence and machine learning-based software as a medical device.
WHY IT MATTERS
The AI/ML-Based Software as a Medical Device Action Plan is a project of the Digital Health Center of Excellence at FDA’s Center for Devices and Radiological Health, which launched this past September.
The action plan outlines five next steps FDA intends to take as AI/ML-based SaMD continues to evolve:
- Continuing to develop its own...
Today's Sponsors
Today's Sponsor